Pulmonx Corporation (NASDAQ:LUNG) Receives Consensus Rating of “Hold” from Analysts

Shares of Pulmonx Corporation (NASDAQ:LUNG) have earned an average rating of “Hold” from the seven brokerages that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating on the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $5.5833.

A number of research firms have recently issued reports on LUNG. D. Boral Capital restated a “buy” rating and issued a $14.00 price target on shares of Pulmonx in a research report on Thursday, April 30th. Wall Street Zen downgraded shares of Pulmonx from a “hold” rating to a “sell” rating in a research report on Saturday, May 2nd. Finally, Canaccord Genuity Group reduced their price objective on Pulmonx from $6.00 to $5.00 and set a “buy” rating for the company in a research report on Thursday, March 5th.

Pulmonx Trading Down 0.4%

NASDAQ LUNG opened at $1.28 on Friday. The company’s fifty day moving average price is $1.40 and its two-hundred day moving average price is $1.65. The company has a debt-to-equity ratio of 0.81, a current ratio of 4.91 and a quick ratio of 4.04. Pulmonx has a 12 month low of $1.13 and a 12 month high of $3.88. The company has a market capitalization of $53.86 million, a price-to-earnings ratio of -0.98 and a beta of 0.28.

Pulmonx (NASDAQ:LUNG) last posted its quarterly earnings results on Wednesday, April 29th. The company reported ($0.33) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.33). Pulmonx had a negative net margin of 60.09% and a negative return on equity of 92.94%. The company had revenue of $20.59 million for the quarter, compared to the consensus estimate of $20.43 million. As a group, research analysts predict that Pulmonx will post -1.13 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE boosted its position in Pulmonx by 60.3% during the 1st quarter. Bank of America Corp DE now owns 1,166,826 shares of the company’s stock valued at $1,505,000 after purchasing an additional 439,027 shares during the period. ADAR1 Capital Management LLC lifted its position in Pulmonx by 5.4% in the 1st quarter. ADAR1 Capital Management LLC now owns 374,497 shares of the company’s stock valued at $483,000 after purchasing an additional 19,087 shares during the last quarter. Renaissance Technologies LLC lifted its position in Pulmonx by 9.7% in the 1st quarter. Renaissance Technologies LLC now owns 320,300 shares of the company’s stock valued at $413,000 after purchasing an additional 28,300 shares during the last quarter. Sei Investments Co. bought a new stake in Pulmonx in the 1st quarter valued at about $31,000. Finally, R Squared Ltd bought a new stake in Pulmonx in the 1st quarter valued at about $26,000. Institutional investors and hedge funds own 91.04% of the company’s stock.

About Pulmonx

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.